CSL crashes to 8-year low as $60bn erased

Australia's former healthcare darling hit A$125.78, down 49.91 percent over 12 months and wiping A$60 billion from its market cap after dismal half-year results triggered another confidence collapse. Underlying profit fell 7 percent while reported earnings plunged 81 percent on $1.1 billion in impairments, mostly from intellectual property writedowns at Vifor and Seqirus units. The company's plasma margin recovery to pre-COVID levels has been abandoned entirely, shifting investor expectations from high single-digit growth to low singles with execution risk. Three major downgrades since August 2025 have destroyed management credibility, leaving a blue-chip growth story stranded in value territory with a sub-1.5 percent dividend yield.